An EORTC/ECSG phase I and pharmacokinetics (PK) study of MS209 in combination with docetaxel in patients with progressive solid tumors.

被引：0
|
作者：
Dieras, V
Degardin, M
Benaoudia, R
Bonneterre, J
Pierga, J
Bonneterre, M
Marreaud, S
Lacombe, D
Fumoleau, P
机构：
[1] EORTC Early Clin Study Grp, Brussels, Belgium
[2] Drug Dev Program, Brussels, Belgium
来源：
CLINICAL CANCER RESEARCH | 2001年 / 7卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
437
引用
收藏
页码：3741S / 3742S
页数：2
相关论文
共 50 条
  • [1] Phase I study to determine the safety of MS209 in combination with docetaxel in patients with solid progressive tumor
    Dieras, V
    Bonneterre, J
    Pierga, J
    Bonneterre, M
    Degardin, M
    Marreaud, S
    Lacombe, D
    Fumoleau, P
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S155 - S156
  • [2] Phase I pharmacokinetic (PK) study of daily imatinib in combination with docetaxel for patients with advanced solid tumors.
    Chatta, GS
    Fakih, M
    Ramalingam, S
    Belani, CP
    Ramanathan, RK
    Zamboni, N
    Friedland, D
    Lis, D
    Tutchko, S
    Egorin, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 138S - 138S
  • [3] A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.
    Puglisi, M.
    van Doorn, L.
    Blanco-Codesido, M.
    De Jonge, M. J.
    Moran, K.
    Yang, J.
    Busman, T.
    Franklin, C.
    Mabry, M.
    Krivoshik, A.
    Humerickhouse, R.
    Molife, L. R.
    Eskens, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies
    Diéras, W
    Bonnieterre, J
    Laurence, V
    Degardin, M
    Pierga, JY
    Bonneterre, ME
    Marreaud, S
    Lacombe, D
    Fumoleau, P
    CLINICAL CANCER RESEARCH, 2005, 11 (17) : 6256 - 6260
  • [5] A phase I clinical and pharmacokinetic (PK) study of paclitaxel (P) and docetaxel (D) in patients (PTS) with solid tumors.
    Izquierdo, MA
    Pontón, JL
    García, M
    Navarro, M
    Mesia, R
    Cardenal, F
    Gil, M
    Germá, JR
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S84 - S84
  • [6] Phase I study of ispinesib (SB-715992) in combination with docetaxel in patients with advanced solid tumors.
    Blagden, S
    Seebaran, A
    Molife, R
    Payne, M
    Reid, A
    Protheroe, A
    Kathman, S
    Williams, D
    Bowen, C
    Hodge, J
    Dar, M
    de-Bono, J
    Middleton, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9119S - 9119S
  • [7] A phase I study of lenalidomide and weekly docetaxel in patients with advanced solid tumors.
    Papadopoulos, K
    Mendelson, D
    Preston, GG
    Lopez, AM
    Ricart, AD
    Schwartz, G
    Needle, MN
    Gordon, MS
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9116S - 9116S
  • [8] Phase I and pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
    Papadopoulos, K. P.
    Chu, Q.
    Patnaik, A.
    Mita, M. M.
    Cooper, J.
    Van Maanen, R.
    Lopez-Lazaro, L.
    Lebedinsky, C.
    Rowinsky, E. K.
    Tolcher, A. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 86S - 86S
  • [9] Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors.
    Poveda, Andres
    Oaknin, Ana
    Romero, Ignacio
    Guerrero, Angel
    Farinas-Madrid, Lorena
    Rodriguez-Freixinos, Victor
    Soto-Matos, Arturo
    Peris, Carlos
    Teruel, Marisa
    Lopez-Reig, Raquel
    Lopez-Guerrero, Jose Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
    C.-P. Schneider
    U. Merkel
    U. Grübner
    R. Kath
    K. Höffken
    A. Hoffmann
    Journal of Cancer Research and Clinical Oncology, 2002, 128 : 313 - 318
12345